Lilly Secures Foundayo Approval, Faces 3.2% Efficacy Gap and Invests $10B in AI
Eli Lilly secured FDA approval for its oral obesity therapy Foundayo as Novo Nordisk’s oral semaglutide showed 3.2% greater weight loss in late-stage ORION data, with 84% patient preference. Simultaneously, Lilly announced over $10 billion AI partnerships and Centessa acquisition to diversify R&D and enter sleep–wake disorder markets.
1. Foundayo FDA Approval
Eli Lilly received FDA clearance for its oral obesity therapy, Foundayo (orforglipron), marking a key entry into the growing market for weight-loss pills and challenging injectable dominance.
2. Competitive ORION Efficacy Data
Novo Nordisk’s simulated ORION study indicated its 25 mg oral semaglutide achieved 3.2% greater weight loss than Lilly’s 36 mg orforglipron, and a November patient survey showed 84% preferred semaglutide’s treatment profile.
3. $10 Billion AI and Neuroscience Investment
Lilly committed $2.75 billion to expand its AI partnership with InSilico Medicine and plans a $6.3–7.8 billion acquisition of Centessa Pharmaceuticals to accelerate AI-driven drug discovery and enter the sleep–wake disorders market.
4. Potential Tariff Headwinds
New 100% tariffs on certain drug imports could raise costs for active pharmaceutical ingredients sourced internationally, potentially increasing manufacturing expenses for Lilly’s product pipeline.